A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 887 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 Load more HOT NEWS New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer Black Patients Are More Likely to Die of Cancer—Here’s How One... ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges...
